These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 7910120

  • 1. An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy.
    Kroemer HK, Fromm MF, Bühl K, Terefe H, Blaschke G, Eichelbaum M.
    Circulation; 1994 May; 89(5):2396-400. PubMed ID: 7910120
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Different stereoselective effects of (R)- and (S)-propafenone: clinical pharmacologic, electrophysiologic, and radioligand binding studies.
    Stoschitzky K, Klein W, Stark G, Stark U, Zernig G, Graziadei I, Lindner W.
    Clin Pharmacol Ther; 1990 Jun; 47(6):740-6. PubMed ID: 2162749
    [Abstract] [Full Text] [Related]

  • 5. Stereoselective disposition and pharmacologic activity of propafenone enantiomers.
    Kroemer HK, Funck-Brentano C, Silberstein DJ, Wood AJ, Eichelbaum M, Woosley RL, Roden DM.
    Circulation; 1989 May; 79(5):1068-76. PubMed ID: 2713973
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism.
    Kroemer HK, Fischer C, Meese CO, Eichelbaum M.
    Mol Pharmacol; 1991 Jul; 40(1):135-42. PubMed ID: 1857335
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man.
    Brode E, Müller-Peltzer H, Hollmann M.
    Methods Find Exp Clin Pharmacol; 1988 Nov; 10(11):717-27. PubMed ID: 3221745
    [Abstract] [Full Text] [Related]

  • 11. Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects.
    Mörike KE, Roden DM.
    Clin Pharmacol Ther; 1994 Jan; 55(1):28-34. PubMed ID: 7905369
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Specific and nonspecific effects of beta receptor blockers: stereoselectively different properties exemplified by (R)- and (S)-propranolol].
    Stoschitzky K, Lindner W.
    Wien Med Wochenschr; 1990 Apr 15; 140(6-7):156-62. PubMed ID: 1971978
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Beta-blocking effect of propafenone based on spectral analysis of heart rate variability.
    Lombardi F, Torzillo D, Sandrone G, Dalla Vecchia L, Finocchiaro ML, Bernasconi R, Cappiello E.
    Am J Cardiol; 1992 Oct 15; 70(11):1028-34. PubMed ID: 1357951
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Concentration dependent stereoselectivity of propafenone N-depropylation metabolism with human hepatic recombinant CYP1A2.
    Zhou Q, Yao TW, Yu YN, Zeng S.
    Pharmazie; 2003 Sep 15; 58(9):651-3. PubMed ID: 14531463
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Quantitation of R- and S-propafenone and of the main metabolite in plasma.
    Böhm R, Ellrich R, Koytchev R.
    Pharmazie; 1995 Aug 15; 50(8):542-5. PubMed ID: 7568317
    [Abstract] [Full Text] [Related]

  • 20. Lack of clinically significant beta-blocking effect of propafenone.
    Cheriex EC, Krijne R, Brugada P, Heymeriks J, Wellens HJ.
    Eur Heart J; 1987 Jan 15; 8(1):53-6. PubMed ID: 2880719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.